Inactive Instrument

News Qiagen NV Nasdaq

Equities

Qiagen N : 2024 QIAGEN N.V. Annual General Meeting of Shareholders Presentation	May. 08	PU
Qiagen N : 2023 Annual Report 2023 Annual Financial Report	May. 08	PU
Qiagen, US FBI to Jointly Develop Digital PCR Assay for Forensics	May. 08	MT
QIAGEN partners with FBI to develop digital PCR assay for QIAcuity for use in forensics	May. 07	AQ
QIAGEN Partners with FBI to Develop Digital PCR Assay for QIAcuity for Use in Forensics	May. 07	CI
Qiagen N : Q1 2024 Results Investor Introduction	May. 03	PU
QIAGEN enhances bioinformatics workflows with new secondary analysis solution for oncology and inherited disease applications	May. 02	AQ
QIAGEN Announces the Availability of QCI Secondary Analysis	May. 02	CI
Qiagen N : First Quarter 2024 SEC Filing	May. 02	PU
QIAGEN NV : Berenberg reaffirms its Buy rating	Apr. 30	ZD
QIAGEN : A decent start to 2024; guidance unchanged	Apr. 30
QIAGEN NV : Deutsche Bank reiterates its Buy rating	Apr. 30	ZD
Qiagen Seeks Acquisitions	Apr. 30	CI
Transcript : Qiagen N.V., Q1 2024 Earnings Call, Apr 30, 2024	Apr. 30
Q1 2024 Results Conference Call Presentation: April 30, 2023	Apr. 30	PU
Qiagen N : QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance	Apr. 30	PU
QIAGEN NV : Jefferies remains Neutral	Apr. 30	ZD
QIAGEN NV : UBS remains Neutral	Apr. 30	ZD
QIAGEN NV : UBS remains Neutral	Apr. 30	ZD
QIAGEN NV : UBS sticks Neutral	Apr. 30	ZD

No results for this search

QIAGEN : A decent start to 2024; guidance unchanged

April 30, 2024 at 09:32 am EDT